Effect of short-term rosiglitazone therapy in peritoneal dialysis patients.
van Hooland
Simon
S
Department of Nephrology, Universitair Ziekenhuis Brussel, Brussels, Belgium. simon00028@hotmail.com
Boey
Olivier
O
Van der Niepen
Patricia
P
Van den Branden
Christiane
C
Verbeelen
Dierik
D
D000284:Administration, Oral; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D047495:PPAR gamma / Q000819:agonists; D010530:Peritoneal Dialysis / Q000379:methods*; D010865:Pilot Projects; D011446:Prospective Studies; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone